Regeneron Pharmaceuticals (NASDAQ:REGN) reported Q2 non-GAAP earnings of $10.24 diluted share, up from $9.77 a year earlier.
Analysts polled by Capital IQ expected $9.90.
Revenue for the quarter ended June 30 was $3.16 billion, up from $2.86 billion a year earlier.
Analysts surveyed by Capital IQ expected $3.02 billion.
The company now anticipates 2023 capital expenditures in the range of $760 million to $830 million versus its previous guidance of $800 million to $900 million.